about
Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride.Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour.A Step-by-Step Clinical Approach for the Management of Neuroendocrine Tumours.Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617.Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617.Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.[18F]Fluorodeoxyglucose Positron Emission Tomography Reveals a Complete Remission of Refractory Metastatic Melanoma after Therapy with Ipilimumab.Theranostics in nuclear medicine practiceDiagnostic accuracy of [99mTc]Tc-Sestamibi in the assessment of thyroid nodules.Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy.Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer.PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer.68Ga-PSMA-11 PET Represents the Tumoricidal Effect of 223Ra in a Patient With Castrate-Resistant Metastatic Prostate Cancer.Successful Repeated Peptide Receptor Radionuclide Therapies in Renal Neuroendocrine Tumor With Osseous Metastasis.68Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with 223Ra: Proof of Concept.Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis.The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance TherapyThe value of tumor markers in men with metastatic prostate cancer undergoing [177 Lu]Lu-PSMA therapyPeptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine TumorsOutcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer
P50
Q33441176-476FB01A-1DD4-40A8-9A67-308D8B1ABA88Q38936576-0AB57E29-6657-410F-935C-81C10D588867Q39093936-8DBD2FD6-B3B9-456C-AC9A-1FFBE37BD35DQ40208178-F66A67C8-01D8-4D15-9EAE-34F88D385CC4Q40597368-4C0E0E4E-3F53-47AD-9440-E571FCEB7A34Q40913769-4F57688A-C4CB-49BC-9F86-894B4C4CB137Q42078928-F343A122-C97C-4922-8640-3E4224BA1E37Q42373162-0350C87F-951F-4AD3-BFEB-E86DEE6BF6C5Q47128358-22D94543-5967-4111-A35C-98C7A1042649Q47158291-D65585E7-887B-4719-BDAD-6762A0052D94Q47603267-DF8D1D44-0F63-4BAE-A0D9-4C3E76DFAC05Q48194472-CBD8A9F3-3C7A-4763-A6BF-B407E8ED8D98Q50777449-B6D051DB-2071-459A-BACD-6547E0D2CFE7Q51646815-47EDD124-894B-4717-A24E-9D288559C4A8Q51769252-11430C90-3004-4A39-A115-C582C0366F4EQ53744593-9E432ECA-F575-42E9-BEE3-B5C4B132E4B7Q53790732-4E65BAFE-1D79-4C76-9322-9784803403DFQ89293927-E3FDAEC3-1327-4F29-9D7E-3266658DEBFEQ90451359-515773A1-05DF-4FFB-8BC2-43FFB7F98B0BQ92744948-21E9736F-E64C-4029-8C8C-2E2BE1727608Q93361492-AC12FB70-8A84-4FCA-8BC9-A8DD1ED0B458
P50
description
investigador
@es
researcher
@en
name
Anna Yordanova
@en
type
label
Anna Yordanova
@en
prefLabel
Anna Yordanova
@en
P31
P496
0000-0001-5881-2819